RxDoctor Payments Data

Pedro Diaz, MD

Cardiovascular Disease · Hialeah, FLNPI 1578532800

Payments from drug & device makers

$78,080in general payments, 2019–2025

Across 316 payments — averaging $247.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Esperion Therapeutics, Inc.$67K
  • Biotronik Inc.$4K
  • Abbott$1K
  • Novartis$1K
  • Pfizer$654
  • E.r. Squibb & Sons, L.L.C.$481
  • plus $3K from 23 others

What the payments were for

  • Speaking & faculty fees$62,70080%
  • Food & beverage$15,23320%
  • Education$1480%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$78,080 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$324,391
Medicare patients
234
Services billed
1,537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban953$858,725
VyndamaxTafamidis13$295,630
EntrestoSacubitril/Valsartan236$257,421
XareltoRivaroxaban86$78,878
FarxigaDapagliflozin Propanediol76$68,839
OzempicSemaglutide48$50,775
MounjaroTirzepatide28$32,600
BrilintaTicagrelor44$27,271
TradjentaLinagliptin29$22,836
VascepaIcosapent Ethyl31$20,177
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$19,975
JanuviaSitagliptin Phosphate19$17,211
JardianceEmpagliflozin27$16,509
Ranolazine ErRanolazine174$15,682
JanumetSitagliptin Phos/Metformin Hcl22$14,609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$654$1,154,355966 claims
NovartisEntresto$1,136$257,421236 claims
AstraZenecaFarxiga, Brilinta, Symbicort, Nexium$320$103,975151 claims
Johnson & JohnsonXarelto$64$78,87886 claims
Novo NordiskOzempic$73$50,77548 claims
MerckJanuvia, Janumet$24$31,82141 claims
Esperion Therapeutics, Inc.Nexlizet$66,898$9,86416 claims
Arbor Pharmaceuticals, Inc.Edarbi$69$5,79220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Hialeah

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →